먼저 BBB1은 12일 자사 CML 치료제인 FFF1에 대해 "BBB2의 CML 치료제인 FFF2(성분명:이매티닙)를 복용한 환자의 약 24개월간 경과를 추적한 결과 FFF3의 치료율이 높게 나타났다"고 밝혔다.
First, on the 12th, BBB1 announced that "the treatment rate of FFF3 was high as a result of tracking the progress of patients who took FFF2, a CML treatment of BBB2, for about 24 months."